Monoclonal antibody 14C5 targets integrin alphavbeta5

Area of Science:

• Immunology
• Oncology
• Cell Biology

Background:

• Integrins are crucial cell surface receptors involved in cell adhesion and signaling.
• The integrin alphavbeta5 plays a role in angiogenesis and tumor progression.
• Monoclonal antibodies (mAbs) are valuable tools for cancer research and therapy.

Purpose of the Study:

• To identify and characterize the antigen recognized by monoclonal antibody (mAb) 14C5.
• To investigate the expression pattern of antigen 14C5 in cancer cell lines and tissues.
• To determine the potential of mAb 14C5 as a diagnostic or therapeutic agent.

Main Methods:

• Flow cytometry was used to compare antigen 14C5 expression with integrin subunits and heterodimers.
• Immunohistochemistry was employed to evaluate tissue distribution in colon and lung cancer.
• Functional blocking assays with anti-alphavbeta5 antibody (P1F6) were performed.

Main Results:

• Antigen 14C5 expression closely mirrored alphavbeta5 expression in epithelial cancer cell lines.
• mAb 14C5 binding was blocked by P1F6, and mAb 14C5 bound alphavbeta5-expressing cells.
• Antigen 14C5 was detected in colon (50%) and non-small cell lung cancers (squamous and adenocarcinoma), with significant stromal expression.

Conclusions:

• Monoclonal antibody 14C5 specifically binds to the vascular integrin alphavbeta5.
• mAb 14C5 demonstrates potential as a screening agent for selecting patients for anti-alphavbeta5 therapies.
• This research opens avenues for targeted cancer treatment strategies based on integrin expression.